Prof Stephen Gillespie

Prof Stephen Gillespie
Sir James Black Chair of Medicine



data source: symbiosis

Research Overview from research@st-andrews

Stephen Gillespie has worked in Kenya researching the relationship between malaria and lower respiratory tract infection and the prevalence of parasitic infection in children in Kilifi, Kenya. He has investigated a cholera epidemic and vaccine failures in Guerrero, Mexico. He has been working in collaboration with colleagues at Kilimanjaro Christian Medical Centre since 1988 where he has, variously, studied respiratory and parasite diagnostics and novel antimalarials, anti-helminthics and anti tuberculosis agents. His main research activity is in the area of tuberculosis drug development.

For the last twenty five years Stephen Gillespie has been involved in various aspects of  tuberculosis diagnosis and drug development. This has included the evaluation of new candidate antituberculosis agents in vitro. This work has expanded into studies of the molecular mechanisms of resistance and the development of model systems to measure the fitness deficits found in resistant strains. He has been involved in the development of fluoroquinolones for tuberculosis having performed early bacterial activity studies and clinical trials of ciprofloxacin. More recently he has led the group working on the clinical development of moxifloxacin in collaboration with the Global Alliance for TB Drug Development as Chief Investigator of the REMox TB study. He later went on to be the coordinating investigator for the TB Alliance STAND trial (Shortening Treatment by Advancing New Drugs). He is also one of the Chief Investigators of the PanACEA consortium that links European and African research groups in enhancing anti-tuberculosis therapy.  

He has an extensive record of developing novel mirobiological diagnostics.  Most recently, he has developed SLIC (Scattered Light Integrating Collector),  which performs phenotypic antibiotic susceptibility testing in less than 30 minutes. This innovation recently won a Longitude Prize Discovery Award. In addition he has developed the Molecular Bacterial Load Assay, an innovative way of detecting, quantifiying and determining the viability of bacteria in a single test that allows both diagnosis and the monitoring of treatment response.


Recent publications listed in research@st-andrews
25 (of 113 published available) for shg3 (source: University of St Andrews PURE)
Please click title of any item for full details

Heat-inactivation renders sputum safe and preserves Mycobacterium tuberculosis RNA for downstream molecular tests Wilber Sabiiti, Khalide Azam, Ezembro Esmeraldo, Nilesh Bhatt, Andrea Rachow, Stephen Henry Gillespie
Journal of Clinical Microbiology 2019 vol.57 
Pseudomonas aeruginosa intensive care unit outbreak Katarina Oravcova, Miguel Pinheiro, Matthew Holden, Gabby Phillips, Jane F. Turton, Stephen Henry Gillespie
Journal of Hospital Infection 2018 vol.98 pp.282-288
A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses Robin J Svensson, Rob E Aarnoutse, Andreas H Diacon, Rodney Dawson, Stephen Henry Gillespie, Martin J Boeree, Ulrika S. H. Simonsson
Clinical Pharmacology & Therapeutics 2018 vol.103 pp.674-683
A spatially heterogeneous network-based metapopulation software model applied to the simulation of a pulmonary tuberculosis infection Ruth Bowness, Simon Andrew Dobson, Stephen Henry Gillespie
Applied Network Science 2018 vol.3 
Comparison of different treatments for isoniazid-resistant tuberculosis Federica Fregonese, Shama D Ahuja, Onno W Akkerman, Denise Arakaki-Sanchez, Irene Ayakaka, Parvaneh Baghaei, Didi Bang, Mayara Bastos, Andrea Benedetti, Maryline Bonnet, Adithya Cattamanchi, Peter Cegielski, Jung-Yien Chien, Helen Cox, Martin Dedicoat, Connie Erkens, Patricio Escalante, Dennis Falzon, Anthony J Garcia-Prats, Medea Gegia, Stephen Henry Gillespie, Judith R Glynn, Stefan Goldberg, David Griffith, Karen R Jacobson, James C Johnston, Edward C Jones-López, Awal Khan, Won-Jung Koh, Afranio Kritski, Zhi Yi Lan, Jae Ho Lee, Pei Zhi Li, Ethel L Maciel, Rafael Mello Galliez, Corinne S C Merle, Melinda Munang, Gopalan Narendran, Viet Nhung Nguyen, Andrew Nunn, Akihiro Ohkado, Jong Sun Park, Patrick P J Phillips, Chinnaiyan Ponnuraja, Randall Reves, Kamila Romanowski, Kwonjune Seung, H Simon Schaaf, Alena Skrahina, Dick van Soolingen, Payam Tabarsi, Anete Trajman, Lisa Trieu, Velayutham V Banurekha, Piret Viiklepp, Jann-Yuan Wang, Takashi Yoshiyama, Dick Menzies
The Lancet Respiratory Medicine 2018 vol.6 pp.265-275
Detecting phenotypically resistant Mycobacterium tuberculosis using wavelength modulated Raman spectroscopy Mingzhou Chen, Simon O Clark, Ann Williams, Kishan Dholakia, Stephen Henry Gillespie
 2018 pp.41-50
Forecasting clinical dose-response from pre-clinical studies in tuberculosis research - translational predictions with rifampicin Sebastian G. Wicha, Oskar Clewe, Robin J. Svensson, Stephen Henry Gillespie, Yanmin Hu, Anthony R.m. Coates, Ulrika S.h. Simonsson
Clinical Pharmacology & Therapeutics  vol.Early View 
Gender differences in tuberculosis treatment outcomes M. E. Murphy, G. H. Wills, S. Murthy, C. Louw, A. L. C. Bateson, R. D. Hunt, T. D. McHugh, A. J. Nunn, S. K. Meredith, C. M. Mendel, M. Spigelman, A. M. Crook, Stephen Henry Gillespie,
BMC Medicine 2018 vol.16 
Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations Robin J Svensson, Elin M Svensson, Rob E Aarnoutse, Andreas H Diacon, Rodney Dawson, Stephen Henry Gillespie, Mischka Moodley, Martin J Boeree, Ulrika S H Simonsson
Journal of Infectious Diseases  vol.In press 
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study Conor Tweed, Genevieve Helen Wills, Angela M. Crook, Rodney Dawson, Andreas H. Diacon, Cheryl E. Louw, Timothy D. McHugh, Carl Mendel, Sarah Meredith, Lerato Mohapi, Michael E. Murphy, Stephen Murray, Sara Murthy, Andrew J. Nunn, Patrick P. J. Phillips, Kasha Singh, M. Spigelman, Stephen Henry Gillespie
BMC Medicine 2018 vol.16 
Modelling the effects of bacterial cell state and spatial location on tuberculosis treatment Ruth Bowness, Mark Andrew Joseph Chaplain, Gibin G. Powathil, Stephen Henry Gillespie
Journal of Theoretical Biology 2018 vol.446 pp.87-100
Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis Yingjun Liu, Henry Pertinez, Geraint R Davies, Stephen Henry Gillespie, Anthony R Coates, Yanmin Hu
Antimicrobial Agents and Chemotherapy 2018 vol.62 
OMNIgene.SPUTUM suppresses contaminants whilst maintaining Mycobacterium tuberculosis viability and obviates cold-chain transport Khalide Azam, Nureisha Cadir, Carla Madeira, Stephen Henry Gillespie, Wilber Sabiiti
ERJ Open Research 2018 vol.4 
Phenotypic changes on Mycobacterium tuberculosis-specific CD4 T cells as surrogate markers for tuberculosis treatment efficacy Mohamed I. M. Ahmed, Nyanda E. Ntinginya, Gibson Kibiki, Hadija Semvua, Stellah Mpagama, Charles Mtabho, Elmar Saathoff, Kathrin Held, Rebecca Loose, Inge Kroidl, Mkunde Chachage, Ulrich von Both, Antelmo Haule, Anna-Maria Mekota, Martin J. Boeree, Stephen Henry Gillespie, Michael Hoelscher, Norbert Heinrich, Christof Geldmacher,
Frontiers in Immunology 2018 vol.9 
Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis S. E. Murthy, F. Chatterjee, A. Crook, R. Dawson, C. Mendel, M. E. Murphy, S. R. Murray, A. J. Nunn, P. P. J. Phillips, Kasha P. Singh, T. D. McHugh, Stephen Henry Gillespie,
BMC Medicine 2018 vol.16 
The impact of repeated NALC/NaOH- decontamination on the performance of Xpert MTB/RIF assay Andrea Rachow, Elmar Saathoff, Daniel Mapamba, Chacha Mangu, Gabriel Rojas-Ponce, Nyanda E. Ntinginya, Martin Boeree, Norbert Heinrich, Stephen Henry Gillespie, Michael Hoelscher,
Tuberculosis  vol.In press 
The potential for treatment shortening with higher rifampicin doses Elin M Svensson, Robin J Svensson, Lindsey H M Te Brake, Martin J Boeree, Norbert Heinrich, Sarah Konsten, Gavin Churchyard, Rodney Dawson, Andreas H Diacon, Gibson S Kibiki, Lilian T Minja, Nyanda E Ntingiya, Ian Sanne, Stephen Henry Gillespie, Michael Hoelscher, Patrick P J Phillips, Ulrika S H Simonsson, Rob Aarnoutse
Clinical Infectious Diseases 2018 vol.67 pp.34-41
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study Conor Tweed, Angela M. Crook, Evans I. Amukoye, Rodney Dawson, Andreas H. Diacon, Madeline Hanekom, Timothy D. McHugh, Carl M. Mendel, Sarah K. Meredith, Michael E. Murphy, Saraswathi E. Murthy, Andrew J. Nunn, Patrick P. J. Phillips, Kasha P. Singh, Melvin Spigelman, Genevieve H. Wills, Stephen Henry Gillespie
BMC Infectious Diseases 2018 vol.18 
A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens Patrick P. J. Phillips, Carl M. Mendel, Andrew J. Nunn, Timothy D. McHugh, Angela M. Crook, Robert Hunt, Anna Bateson, Stephen Henry Gillespie
BMC Medicine 2017 vol.15 
Genomic investigation unmasks evidence of transmission across mycobacterium abscessus cystic fibrosis patients Clare Peters, Devesh Janardan Dhasmana, Kerry Andrea Pettigrew, Ramon Fallon, A-l Seagar, Derek James Sloan, If Laurenson, Matthew Holden, Stephen Henry Gillespie
Thorax 2017 vol.72 pp.A56-A56
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis Martin J Boeree, Norbert Heinrich, Rob Aarnoutse, Andreas H Diacon, Rodney Dawson, Sunita Rehal, Gibson S Kibiki, Gavin Churchyard, Ian Sanne, Nyanda E Ntinginya, Lilian T Minja, Robert D Hunt, Salome Charalambous, Madeleine Hanekom, Hadija H Semvua, Stellah G Mpagama, Christina Manyama, Klaus Reither, Robert S Wallis, Amour Venter, Kim Narunsky, Anka Mekota, Sonja Henne, Angela Colbers, Georgette Plemper van Balen, Stephen Henry Gillespie, Patrick P J Phillips, Michael Hoelscher
Lancet Infectious Diseases 2017 vol.17 pp.39-49
Improved power for TB phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods Robin Svensson, Stephen Henry Gillespie, Ulrika Simonsson
Journal of Antimicrobial Chemotherapy 2017 vol.72 pp.2311-2319